

Jingjing Qian

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/9395508/publications.pdf>

Version: 2024-02-01

59
papers

768
citations

567144

15
h-index

580701

25
g-index

59
all docs

59
docs citations

59
times ranked

1148
citing authors

#	ARTICLE	IF	CITATIONS
1	Association of Chronic Obstructive Pulmonary Disease Maintenance Medication Adherence With All-Cause Hospitalization and Spending in a Medicare Population. <i>American Journal of Geriatric Pharmacotherapy</i> , 2012, 10, 201-210.	3.0	102
2	Impact of eHealth on medication adherence among patients with asthma: A systematic review and meta-analysis. <i>Respiratory Medicine</i> , 2019, 149, 59-68.	1.3	83
3	Prevalence of depressive symptoms and predictors of treatment among U.S. adults from 2005 to 2010. <i>General Hospital Psychiatry</i> , 2014, 36, 330-336.	1.2	72
4	Association between depression and maintenance medication adherence among Medicare beneficiaries with chronic obstructive pulmonary disease. <i>International Journal of Geriatric Psychiatry</i> , 2014, 29, 49-57.	1.3	41
5	Influencers of generic drug utilization: A systematic review. <i>Research in Social and Administrative Pharmacy</i> , 2018, 14, 619-627.	1.5	39
6	Prevention of Trastuzumab and Anthracycline-induced Cardiotoxicity Using Angiotensin-converting Enzyme Inhibitors or β -blockers in Older Adults With Breast Cancer. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 2018, 41, 909-918.	0.6	36
7	Impact of maintenance therapy on hospitalization and expenditures for medicare beneficiaries with chronic obstructive pulmonary disease. <i>American Journal of Geriatric Pharmacotherapy</i> , 2010, 8, 441-453.	3.0	33
8	Effects of Depression Diagnosis and Antidepressant Treatment on Mortality in Medicare Beneficiaries with Chronic Obstructive Pulmonary Disease. <i>Journal of the American Geriatrics Society</i> , 2013, 61, 754-761.	1.3	25
9	Influence of prescription monitoring programs on analgesic utilization by an insured retiree population. <i>Pharmacoepidemiology and Drug Safety</i> , 2012, 21, 1261-1268.	0.9	24
10	Cardiotoxicity in targeted therapy for breast cancer: A study of the FDA adverse event reporting system (FAERS). <i>Journal of Oncology Pharmacy Practice</i> , 2017, 23, 93-102.	0.5	23
11	Comparison of Outcomes Following a Switch From a Brand to an Authorized Versus Independent Generic Drug. <i>Clinical Pharmacology and Therapeutics</i> , 2018, 103, 310-317.	2.3	20
12	Comparison of Generic-to-Brand Switchback Rates Between Generic and Authorized Generic Drugs. <i>Pharmacotherapy</i> , 2017, 37, 429-437.	1.2	19
13	Comparison of brand versus generic antiepileptic drug adverse event reporting rates in the U.S. Food and Drug Administration Adverse Event Reporting System (FAERS). <i>Epilepsy Research</i> , 2017, 135, 71-78.	0.8	19
14	Disclosure of industry payments to prescribers: industry payments might be a factor impacting generic drug prescribing. <i>Pharmacoepidemiology and Drug Safety</i> , 2017, 26, 819-826.	0.9	17
15	Associations of depression diagnosis and antidepressant treatment with mortality among young and disabled Medicare beneficiaries with COPD. <i>General Hospital Psychiatry</i> , 2013, 35, 612-618.	1.2	15
16	The Association Between Patient Sociodemographic Characteristics and Generic Drug Use: A Systematic Review and Meta-analysis. <i>Journal of Managed Care & Specialty Pharmacy</i> , 2018, 24, 252-264.	0.5	14
17	Impact of U.S. federal and state generic drug policies on drug use, spending, and patient outcomes: A systematic review. <i>Research in Social and Administrative Pharmacy</i> , 2020, 16, 736-745.	1.5	14
18	Mixed Approach Retrospective Analyses of Suicide and Suicidal Ideation for Brand Compared with Generic Central Nervous System Drugs. <i>Drug Safety</i> , 2018, 41, 363-376.	1.4	12

#	ARTICLE	IF	CITATIONS
19	Trends in botanical dietary supplement use among US adults by cancer status: The National Health and Nutrition Examination Survey, 1999 to 2014. <i>Cancer</i> , 2018, 124, 1207-1215.	2.0	12
20	Methodological Considerations for Comparison of Brand Versus Generic Versus Authorized Generic Adverse Event Reports in the US Food and Drug Administration Adverse Event Reporting System (FAERS). <i>Clinical Drug Investigation</i> , 2017, 37, 1143-1152.	1.1	11
21	Brand vs generic adverse event reporting patterns: An authorized generic-controlled evaluation of cardiovascular medications. <i>Journal of Clinical Pharmacy and Therapeutics</i> , 2018, 43, 327-335.	0.7	9
22	Risk Factors of Fluoropyrimidine Induced Cardiotoxicity among Cancer Patients: A Systematic Review and Meta-analysis. <i>Critical Reviews in Oncology/Hematology</i> , 2021, 162, 103346.	2.0	9
23	Comparative effectiveness and safety of eribulin in advanced or metastatic breast cancer: a systematic review and meta-analysis. <i>Critical Reviews in Oncology/Hematology</i> , 2021, 163, 103375.	2.0	9
24	Treatment patterns among breast cancer patients in the United States using two national surveys on visits to physicians' offices and hospital outpatient departments. <i>Research in Social and Administrative Pharmacy</i> , 2015, 11, 708-720.	1.5	7
25	Safety of dietary supplements use among patients with cancer: A systematic review. <i>Critical Reviews in Oncology/Hematology</i> , 2020, 152, 103013.	2.0	7
26	Adverse event reporting patterns of concomitant botanical dietary supplements with CYP3A4 interactive & CYP3A4 non-interactive anticancer drugs in the U.S. Food and Drug Administration Adverse Event Reporting System (FAERS). <i>Expert Opinion on Drug Safety</i> , 2019, 18, 145-152.	1.0	6
27	Disparities in the appropriateness of medication use: Analysis of the REasons for Geographic And Racial Differences in Stroke (REGARDS) population-based cohort study. <i>Research in Social and Administrative Pharmacy</i> , 2020, 16, 1702-1710.	1.5	6
28	The impact of cognitive impairment on survival and medication adherence among older women with breast cancer. <i>Breast Cancer</i> , 2021, 28, 277-288.	1.3	6
29	Safety of Marketed Cancer Supportive Care Biosimilars in the US: A Disproportionality Analysis Using the Food and Drug Administration Adverse Event Reporting System (FAERS) Database. <i>BioDrugs</i> , 2021, 35, 239-254.	2.2	6
30	Comparisons of adverse event reporting for colistin versus polymyxin B using the US Food and Drug Administration Adverse Event Reporting System (FAERS). <i>Expert Opinion on Drug Safety</i> , 2021, 20, 603-609.	1.0	6
31	Characteristics and Comparison of Adverse Events of Coronavirus Disease 2019 Vaccines Reported to the United States Vaccine Adverse Event Reporting System Between 14 December 2020 and 8 October 2021. <i>Frontiers in Medicine</i> , 2022, 9, 826327.	1.2	6
32	Trends in gender and race/ethnicity of PharmD students and faculty in US pharmacy schools. <i>Currents in Pharmacy Teaching and Learning</i> , 2021, 13, 1408-1413.	0.4	5
33	Using Machine Learning Approaches to Predict Short-Term Risk of Cardiotoxicity Among Patients with Colorectal Cancer After Starting Fluoropyrimidine-Based Chemotherapy. <i>Cardiovascular Toxicology</i> , 2022, 22, 130-140.	1.1	5
34	Increasing use of immunization information systems for routine vaccinations in independent community pharmacies: A randomized controlled trial. <i>Journal of the American Pharmacists Association: JAPhA</i> , 2022, 62, 1270-1279.e2.	0.7	5
35	Video-Observed Therapy Versus Directly Observed Therapy in Patients With Tuberculosis. <i>American Journal of Preventive Medicine</i> , 2022, 62, 450-458.	1.6	5
36	Factors associated with psychotropic prescriptions, psychiatric hospitalization, and spending among Medicare beneficiaries under 65. <i>Disability and Health Journal</i> , 2015, 8, 424-433.	1.6	4

#	ARTICLE	IF	CITATIONS
37	Communicating benefits and risks of generic drugs to consumers: Patient and caregiver opinions of two FDA-developed educational materials. <i>Research in Social and Administrative Pharmacy</i> , 2019, 15, 1489-1493.	1.5	4
38	Patient preferences for medication adherence financial incentive structures: A discrete choice experiment. <i>Research in Social and Administrative Pharmacy</i> , 2021, 17, 1800-1809.	1.5	4
39	Does public perception bias lead to more frequent reporting of adverse events: branded vs generic drugs. <i>Expert Opinion on Drug Safety</i> , 2018, 17, 753-756.	1.0	3
40	Screening for CYP3A4 inhibition and induction coupled to parallel artificial membrane permeability assay (PAMPA) for prediction of botanical-drug interactions: The case of aÃand maca. <i>Phytomedicine</i> , 2019, 59, 152915.	2.3	3
41	Healthcare provider opinions about a generic drug educational newsletter. <i>Research in Social and Administrative Pharmacy</i> , 2020, 16, 1228-1236.	1.5	3
42	Generic levothyroxine initiation and substitution among Medicare and Medicaid populations: a new user cohort study. <i>Endocrine</i> , 2020, 68, 336-348.	1.1	3
43	Methodological similarities and variations among EQ-5D-5L value set studies: a systematic review. <i>Journal of Medical Economics</i> , 2022, 25, 571-582.	1.0	3
44	Assessing barriers and increasing use of immunization information systems in independent community pharmacies: Study protocol for a randomized controlled trial. <i>Research in Social and Administrative Pharmacy</i> , 2020, 16, 987-992.	1.5	2
45	The association of continuity of care and risk of mortality in breast cancer patients with cardiometabolic comorbidities. <i>Journal of Psychosocial Oncology</i> , 2021, , 1-15.	0.6	2
46	Association between Higher Generic Drug Use and Medicare Part D Star Ratings: An Observational Analysis. <i>Value in Health</i> , 2018, 21, 1186-1191.	0.1	1
47	Authors'ÃReply to CourtneyÃSuggs and ColleaguesÃ™ Comment on: ÃMixed Approach Retrospective Analyses of Suicide and Suicidal Ideation for Brand Compared with Generic Central Nervous System DrugsÃ. <i>Drug Safety</i> , 2018, 41, 1423-1424.	1.4	1
48	Generic escitalopram initiation and substitution among Medicare beneficiaries: A new user cohort study. <i>PLoS ONE</i> , 2020, 15, e0232226.	1.1	1
49	Patient and caregiver opinions about an FDA-developed generic drug educational handout: A pilot cross-sectional survey. <i>Journal of the American Pharmacists Association: JAPhA</i> , 2021, 61, e120-e128.	0.7	1
50	Association between prior use of anti-diabetic medication and breast cancer stage at diagnosis. <i>Expert Opinion on Drug Safety</i> , 2021, 20, 235-243.	1.0	1
51	Patient factors associated with oral generic olanzapine initiation and substitution among Medicaid beneficiaries: a new user cohort study. <i>Current Medical Research and Opinion</i> , 2021, 37, 655-664.	0.9	1
52	AuthorÃ™s Reply to Joerg Putzke et al. Comment on: ÃSafety of Marketed Cancer Supportive Care Biosimilars in the US: A Disproportionality Analysis Using the Food and Drug Administration Adverse Event Reporting System (FAERS) DatabaseÃ. <i>BioDrugs</i> , 2021, 35, 375-377.	2.2	1
53	Perceived appropriateness of medication adherence incentives. <i>Journal of Managed Care & Specialty Pharmacy</i> , 2021, 27, 772-778.	0.5	1
54	Disparities in Cognitive Impairment With Anticholinergic Drug Use. <i>Neurology: Clinical Practice</i> , 2021, 11, e277-e286.	0.8	1

#	ARTICLE	IF	CITATIONS
55	Oral generic tacrolimus initiation and substitution in the Medicaid population: a new user cohort study. <i>Current Medical Research and Opinion</i> , 2020, 36, 1533-1540.	0.9	0
56	The association between antidepressants use and development of cognitive impairment among older women diagnosed with breast cancer. <i>European Geriatric Medicine</i> , 2020, 11, 1017-1026.	1.2	0
57	Physical function before and after initial treatment among older adults with localized or regional stage prostate cancer. <i>Journal of Geriatric Oncology</i> , 2021, , .	0.5	0
58	Real world evidence in effectiveness, safety, and cost savings of generic levothyroxine: a systematic review. <i>Endocrine</i> , 2021, 74, 228-234.	1.1	0
59	Individuals'™ preference for financial over social incentives for medication adherence. <i>Journal of the American Pharmacists Association: JAPhA</i> , 2021, , .	0.7	0